Literature DB >> 26307097

Diagnosis and therapy of antiphospholipid syndrome.

Vittorio Pengo, Gentian Denas, Seena J Padayattil, Giacomo Zoppellaro, Elisa Bison, Alessandra Banzato, Ariela Hoxha, Amelia Ruffatti.   

Abstract

Antiphospholipid syndrome (APS) is a clinical condition that has not been well defined yet. Although the clinical component is well established, the laboratory part is a mood issue. According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti β2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies. According to test positivity, patients are classified into categories in clinical studies. However, it is now clear that classification categories have a different impact on the clinical course of APS. Indeed, patients and healthy carriers with a full positive antibody profile (triple positivity) are those at the highest risk of events. Patients with a single test positivity are those at a lower risk. In this review, on the basis of a laboratory profile, we grade the diagnosis of APS into definite, probable/possible, and uncertain. We also discuss secondary prevention of thrombotic APS, prevention of pregnancy morbidity, and treatment of catastrophic APS. Finally, new tools in laboratory diagnosis and treatment are highlighted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26307097     DOI: 10.20452/pamw.3051

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  8 in total

Review 1.  The Laboratory Diagnosis of the Antiphospholipid Syndrome.

Authors:  Jasmina Ahluwalia; Sreejesh Sreedharanunni
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-22       Impact factor: 0.900

Review 2.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

3.  Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome.

Authors:  Fatima El-Assaad; Steven A Krilis; Bill Giannakopoulos
Journal:  Thromb J       Date:  2016-10-04

Review 4.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

5.  [Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome].

Authors:  Z Y Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

Review 6.  Pigmented purpura and cutaneous vascular occlusion syndromes.

Authors:  Ana Cecilia Lamadrid-Zertuche; Verónica Garza-Rodríguez; Jorge de Jesús Ocampo-Candiani
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

Review 7.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2017-10-02

8.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2020-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.